Tag: Hospitals & Clinics

Auto-injectors Market Size Worth $3.2 Billion by 2026

The global auto-injectors market size is expected to reach USD 3.18 billion by 2026, according to a new report by Grand View Research, Inc, exhibiting a CAGR of 19.5%. Rising incidence of anaphylactic shock and other diseases such as diabetes, rheumatoid, & multiple sclerosis along with increasing approvals of auto-injectors are impelling growth.

Increasing prevalence of life-threatening allergies and rising demand for these devices are expected to aid growth. As per the Food Allergy Research & Education, around 200, 000 people every year need emergency medical care for allergic food reactions.

In addition, increasing approvals are anticipated to drive growth. For instance, in August 2018, U.S. FDA approved the first generic epinephrine auto-injector of Teva Pharmaceuticals to treat emergency allergic reactions, including anaphylaxis. Generic versions of EpiPen Jr & EpiPen of 0.15 mg & 0.3 mg, respectively, are indicated for pediatric and adult patients weighing more than 33 pounds.

Moreover, manufacturers are also developing new products and innovative technologies, which is expected to propel market growth. For instance, in June 2018, AbbVie GK launched Humira, which is a fully human antitumor necrosis factor alpha monoclonal antibody formulation with lock function & injection start & end alerts as well as an inspection window and injects completely in 10 seconds. Demand for these devices is increasing as they are designed in accordance with patient acceptance and compliance. Technological advancements are anticipated to make them more convenient and user-friendly. This is encouraging patients to adopt this technology for chronic illnesses.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/auto-injectors-market

Further key findings from the study suggest:

  • Disposable auto-injectors emerged as the largest segment owing to convenience and ease of use
  • Homecare settings accounted for largest share in end-use segment owing to increasing demand of products for daily administration of insulin
  • North America dominated the auto-injectors market with largest share in 2018. Increasing demand for new technologies along with advanced healthcare infrastructure is expected to boost market growth during the forecast period
  • Asia Pacific is expected to witness fastest growth during the forecast period owing to increasing number of diabetic patients
  • Some of the key players are Eli Lilly; Scandinavian Health Ltd.; AbbVie, Inc.; Amgen; Owen Mumford; Ypsomed; Teva Pharmaceutical; Biogen Idec; Mylan N.V.; Pfizer, Inc.; and Sanofi

Single Lead ECG Equipment Market Worth $487.59 Million By 2025

The global single lead ECG equipment market size is estimated to reach USD 487.59 million by 2025, progressing at a 4.72% CAGR during the forecast period, according to a new report by Grand View Research, Inc.

Emergence of smartphone and mobile-based cardiac monitoring devices has been revolutionized the market in the past few years. Medical device manufacturers continue to invest in development of these products in order to overcome pitfalls associated with conventional means of cardiac assessment. This is, consequently, fostering the growth of the market.

An Indian company Agatsa Software Pvt. Ltd. introduced credit-card-sized ECG monitors, “Sanket”, which measures ECG in 15 seconds and displays results that can be sent to anyone across the globe via email, social media platforms, or SMS. Such advancements in ECG monitoring devices are anticipated to shape the future of the market over the forecast period.

On the other hand, government bodies are undertaking initiatives for improvement in treatment of cardiac disorders in order to satisfy escalating need for inexpensive and portable devices for regular cardiac monitoring as a preventive step. This, in turn, is expected to positively influence the growth of the market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/single-lead-ecg-equipment-market

Further Key Findings From the Study Suggest:

  • Widening base of patients suffering from cardiovascular diseases is expected to augment the single lead portable ECG equipment market
  • The demand for portable ECGs serving home/ambulatory services for risk identification for occurrence of cardiac diseases is projected to grow at a faster pace in the near future
  • The growth of the home/ambulatory segment is supported by continuous improvement in software/algorithms for regular cardiac monitoring
  • Availability of products that can carry out continuous and real time wireless ambulatory patient monitoring is contributing to the growth of the market
  • North America accounted for the largest market share in 2017, owing to well-established healthcare system coupled with rise in prevalence of cardiovascular diseases in the region
  • Presence of several nascent and established participants in the region further drives the R&D and novel product launches in the U.S.
  • Asia Pacific is likely to witness the fastest growth during the forecast period owing to rising patient awareness pertaining to portable technologies as well as increasing healthcare expenditure in developing economies
  • Rise in patient as well as physician awareness and inclination towards medical technology and cloud-based software programs are expected to encourage substantial growth in the region
  • The key players are engaged in launching novel products or algorithms in order to enhance market penetration.